Sapacitabine Shows Promise In Patients Who Fail Vidaza Or Dacogen

Sapacitabine continues to show promise in myelodysplastic syndromes patients who have failed treatment with Vidaza or Dacogen, according to results from an ongoing multi-center Phase 2 trial.

Click here to read the full article on The MDS Beacon.

Free donations by shopping